Literature DB >> 34752754

Capitalizing on the messenger: Intra-tumoral delivery of RNA with a systemic effect.

Patrick A Ott1.   

Abstract

As reported recently in Science Translational Medicine, intra-tumoral administration of mRNAs that encode four cytokines formulated in saline mediates regression of injected and distant murine tumors. The anti-tumor effect, which is also seen in the anti-PD-1-resistant setting and enhanced by checkpoint blockade, is mediated by tumor-specific T cells and natural killer cells.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34752754      PMCID： PMC9261938          DOI： 10.1016/j.ccell.2021.10.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   38.585


  10 in total

1.  Local Delivery of Ox40l, Cd80, and Cd86 mRNA Kindles Global Anticancer Immunity.

Authors:  Ole Audun Werner Haabeth; Timothy R Blake; Colin J McKinlay; Anders A Tveita; Adrienne Sallets; Robert M Waymouth; Paul A Wender; Ronald Levy
Journal:  Cancer Res       Date:  2019-01-28       Impact factor: 12.701

2.  Anchoring of intratumorally administered cytokines to collagen safely potentiates systemic cancer immunotherapy.

Authors:  Noor Momin; Naveen K Mehta; Nitasha R Bennett; Leyuan Ma; Joseph R Palmeri; Magnolia M Chinn; Emi A Lutz; Byong Kang; Darrell J Irvine; Stefani Spranger; K Dane Wittrup
Journal:  Sci Transl Med       Date:  2019-06-26       Impact factor: 17.956

3.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

Authors:  Robert H I Andtbacka; Howard L Kaufman; Frances Collichio; Thomas Amatruda; Neil Senzer; Jason Chesney; Keith A Delman; Lynn E Spitler; Igor Puzanov; Sanjiv S Agarwala; Mohammed Milhem; Lee Cranmer; Brendan Curti; Karl Lewis; Merrick Ross; Troy Guthrie; Gerald P Linette; Gregory A Daniels; Kevin Harrington; Mark R Middleton; Wilson H Miller; Jonathan S Zager; Yining Ye; Bin Yao; Ai Li; Susan Doleman; Ari VanderWalde; Jennifer Gansert; Robert S Coffin
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

4.  Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models.

Authors:  Christian Hotz; Timothy R Wagenaar; Friederike Gieseke; Dinesh S Bangari; Michelle Callahan; Hui Cao; Jan Diekmann; Mustafa Diken; Christian Grunwitz; Andy Hebert; Karl Hsu; Marie Bernardo; Katalin Karikó; Sebastian Kreiter; Andreas N Kuhn; Mikhail Levit; Natalia Malkova; Serena Masciari; Jack Pollard; Hui Qu; Sue Ryan; Abderaouf Selmi; Julia Schlereth; Kuldeep Singh; Fangxian Sun; Bodo Tillmann; Tatiana Tolstykh; William Weber; Lena Wicke; Sonja Witzel; Qunyan Yu; Yu-An Zhang; Gang Zheng; Joanne Lager; Gary J Nabel; Ugur Sahin; Dmitri Wiederschain
Journal:  Sci Transl Med       Date:  2021-09-08       Impact factor: 17.956

5.  Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours.

Authors:  Aslan Mansurov; Jun Ishihara; Peyman Hosseinchi; Lambert Potin; Tiffany M Marchell; Ako Ishihara; John-Michael Williford; Aaron T Alpar; Michal M Raczy; Laura T Gray; Melody A Swartz; Jeffrey A Hubbell
Journal:  Nat Biomed Eng       Date:  2020-04-13       Impact factor: 25.671

6.  Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs.

Authors:  Susannah L Hewitt; Ailin Bai; Dyane Bailey; Kana Ichikawa; John Zielinski; Russell Karp; Ameya Apte; Kristen Arnold; Sima J Zacharek; Maria S Iliou; Khushbu Bhatt; Maija Garnaas; Faith Musenge; Ashley Davis; Nikhil Khatwani; Stephen V Su; Graham MacLean; Samuel J Farlow; Kristine Burke; Joshua P Frederick
Journal:  Sci Transl Med       Date:  2019-01-30       Impact factor: 17.956

7.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

Authors:  J M Kirkwood; M H Strawderman; M S Ernstoff; T J Smith; E C Borden; R H Blum
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

8.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Authors:  Antoni Ribas; Reinhard Dummer; Igor Puzanov; Ari VanderWalde; Robert H I Andtbacka; Olivier Michielin; Anthony J Olszanski; Josep Malvehy; Jonathan Cebon; Eugenio Fernandez; John M Kirkwood; Thomas F Gajewski; Lisa Chen; Kevin S Gorski; Abraham A Anderson; Scott J Diede; Michael E Lassman; Jennifer Gansert; F Stephen Hodi; Georgina V Long
Journal:  Cell       Date:  2017-09-07       Impact factor: 41.582

9.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

Authors:  G Fyfe; R I Fisher; S A Rosenberg; M Sznol; D R Parkinson; A C Louie
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

10.  Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.

Authors:  Antoni Ribas; Theresa Medina; John M Kirkwood; Yousef Zakharia; Rene Gonzalez; Diwakar Davar; Bartosz Chmielowski; Katie M Campbell; Riyue Bao; Heather Kelley; Aaron Morris; David Mauro; James E Wooldridge; Jason J Luke; George J Weiner; Arthur M Krieg; Mohammed M Milhem
Journal:  Cancer Discov       Date:  2021-12-01       Impact factor: 39.397
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.